Suppr超能文献

非肝细胞癌恶性肿瘤的肝移植

Liver Transplant for Nonhepatocellular Carcinoma Malignancy.

作者信息

Haberal Reyhan Nihan

机构信息

Department of Pathology, Başkent University Medical Faculty, Ankara, Turkey.

出版信息

Exp Clin Transplant. 2017 Mar;15(Suppl 2):69-73. doi: 10.6002/ect.TOND16.L18.

Abstract

Liver transplant is now an acceptable and effective treatment for specific nonhepatocellular malignancies. Worldwide, hilar cholangiocarcinoma accounts for 3% of all primary gastrointestinal malignancies and for 10% of primary hepatobiliary malignancies. For patients who have early-stage, unresectable cholangiocarcinoma, liver transplant preceded by neoadjuvant radiotherapy can result in tumor-free margins, accomplish a radical resection, and treat the underlying primary sclerosing cholangitis when present. Hepatic epithelioid hemangioendothelioma is a rare tumor of vascular origin with a variable malignant potential. Excellent results have been reported with liver transplant for patients with unresectable hepatic epithelioid hemangioendothelioma, with 1-year and 10-year survival rates of 96% and 72%. Hepatoblastoma is the most common primary hepatic malignancy in children. The long-term survival rate after transplant ranges from 66% to 77% in patients with unresectable tumors and good response to chemotherapy. Metastatic liver disease is not an indication for liver transplant, with the exception of cases in which the primary tumor is a neuroendocrine tumor. Indication for liver transplant for hepatic metastasis from neuroendocrine tumors is mainly for patients with unresectable tumors and for palliation of medically uncontrollable symptoms. Posttransplant survival in those patients with low tumor activity index is excellent, despite recurrence of the tumor. Some recent data on liver transplant for unresectable hepatic metastases from colorectal cancer have reported limited survival benefits compared with previous reports. However, due to the high rate of tumor recurrence in a very short time after liver transplant, especially in the era of organ shortage, this indication has not been favored by the transplant community. The indications for liver transplant for nonhepatocellular carcinoma malignancy and its limitations have evolved dramatically over the past decades and will continue to be redefined through future research and investigations.

摘要

肝移植现已成为治疗特定非肝细胞恶性肿瘤的一种可接受且有效的方法。在全球范围内,肝门部胆管癌占所有原发性胃肠道恶性肿瘤的3%,占原发性肝胆恶性肿瘤的10%。对于早期、不可切除的胆管癌患者,新辅助放疗后进行肝移植可实现切缘无肿瘤,完成根治性切除,并在存在原发性硬化性胆管炎时对其进行治疗。肝上皮样血管内皮瘤是一种罕见的血管源性肿瘤,恶性潜能各异。对于不可切除的肝上皮样血管内皮瘤患者,肝移植已报告有出色的效果,1年和10年生存率分别为96%和72%。肝母细胞瘤是儿童最常见的原发性肝脏恶性肿瘤。对于不可切除肿瘤且对化疗反应良好的患者,移植后的长期生存率在66%至77%之间。除了原发性肿瘤为神经内分泌肿瘤的情况外,转移性肝病并非肝移植的适应证。神经内分泌肿瘤肝转移的肝移植适应证主要是针对不可切除肿瘤且用于缓解药物无法控制的症状。尽管肿瘤复发,但肿瘤活动指数低的患者移植后生存率良好。最近一些关于不可切除的结直肠癌肝转移肝移植的数据报告显示,与之前的报告相比,生存获益有限。然而,由于肝移植后肿瘤在很短时间内复发率很高,特别是在器官短缺的时代,这一适应证未得到移植界的青睐。在过去几十年中,非肝细胞癌恶性肿瘤的肝移植适应证及其局限性发生了巨大变化,并将通过未来的研究和调查继续重新定义。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验